Overview

NCI Definition: An invasive squamous cell carcinoma arising from the vulva. Risk factors include the human papilloma virus and cigarette smoking. Precursor lesions include the vulvar intraepithelial neoplasia, lichen sclerosus with associated squamous cell hyperplasia, and chronic granulomatous vulvar disease such as granuloma inguinale. Symptoms include vulvar pruritus or irritation, discharge, bleeding, and pain. The following morphologic variants have been identified: keratinizing, non-keratinizing, basaloid, warty, verrucous, keratoacanthoma-like, and squamous cell carcinoma with tumor giant cells. Risk factors for recurrence include advanced stage, tumor diameter greater than 2.5 cm, multifocality, capillary-like space involvement, associated vulvar intraepithelial neoplasia grades 2 or 3, and margins of resection involved by tumor. (WHO, 2003) [1]

Significant Genes in Vulvar Squamous Cell Carcinoma

MLH1 +

MLH3 +

MSH2 +

MSH3 +

MSH6 +

PMS1 +

PMS2 +

Disease Details

Synonyms
Epidermoid Carcinoma of the Vulva, Squamous Cell Carcinoma of Vulva, Vulva Squamous Cell Carcinoma, Epidermoid Cell Carcinoma of Vulva, Vulva Epidermoid Carcinoma, Vulvar Epidermoid Cell Carcinoma, Epidermoid Cell Carcinoma of the Vulva, Vulva Epidermoid Cell Carcinoma, Epidermoid Carcinoma of Vulva, Vulvar Epidermoid Carcinoma, Squamous Cell Carcinoma of the Vulva
Parent(s)
Vulvar Squamous Neoplasm
Children
Bartholin Gland Squamous Cell Carcinoma, Vulvar Keratoacanthoma-Like Carcinoma, Vulvar Verrucous Carcinoma, Vulvar Non-Keratinizing Squamous Cell Carcinoma, and Vulvar Keratinizing Squamous Cell Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.